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(0.2-39.3 cc). Low SRS dose was justified by larger volume, clinical 
history and critical anatomical location. Fixation was performed with 
a 3D-Line invasive frame, and all the patients underwent 
Angiography/CT/MR fusion for the localization of the target and the 
organ at risk. SRS was performed with 6 MV LINAC and MMLC of 3 mm. 
The radiation treatment was administered generally using five 
noncoplanar arcs with a single isocenter.  
Results: All the patients completed the SRS procedure without 
toxicity. Follow-up RM revealed complete obliteration of all AVM nidus 
in 7 out of 22 patients (32%) after 19 months of median follow up 
(range 12- 36).Complete response was seen only when 20 Gy were 
administered. After 12 months of follow up RM documented partial 
obliteration in 3 patients (13%) treated with 16 Gy. Median 15 months 
RM (3-24 months) showed persistent AVM nidus in 12 out of 22 patients 
(55%). 
Conclusions: In our series good response rate was seen in higher dose 
SRS (20 Gy) group. Low dose SRS is an effective and relatively safe 
mean of treating large, complex AVMs that are not suitable to surgery 
or higher dose SRS; obliteration rates for larger AVM are less than for 
small AVM according with literature data. AVM shunt regresses slowly 
over time so overall obliteration rates are further probably limited by 
shorter gap between SRS and radiological check.  
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Purpose/Objective: Our aim is to report the outcome of fractionated 
stereotactic radiationtherapy in the management of optic nerve 
sheath meningiomas.  
Materials and Methods: Between March 2007 and September 2010 a 
total of nine patients with primary benign optic nerve sheath 
meningioma (ONSM) have been treated with fractioned stereotactic 
radiotherapy (FSRT). One patient, from who there was no follow up 
available, was excluded. Results of these patients were analysed in a 
retrospective single centre study.  
Results: After a median follow up of 32 months (range 15-55) growth 
control on MRI was achieved in all 8 patients (100%), and reduction in 
tumour volume in 2 of these patients (25%). A total of 4 patients 
showed improvement of their visual acuity of at least two lines on the 
Snellen chart. A stabilization of vision was seen in 3 patients. 1 
patient was already blind before radiotherapy. Five patients had a 
stable visual field during follow up, 1 patient had an improved visual 
field and 1 patient had a deterioration of the visual field. Pre-existing 
clinical symptoms improved or even disappeared in all patients. Acute 
toxicity was mild and included transient headache in 2 patients, 
transient orbital pain in 2 patients and edema in 2 patients. 
Conclusions: In our series we achieved stable disease and stabilisation 
or improvement of visual acuity in all 8 treated patients. Fractionated 
stereotactic radiotherapy is an effective and save treatment option in 
patients with optic nerve sheath meningiomas. 
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Purpose/Objective: Management of recurrent Glioblastoma 
Multiforme (GBM) following definitive surgical resection, standard 
post-operative radiation therapy and temozolomide is challenging. 
This study analyzes the efficacy and morbidity associated with 
fractionated stereotactic radiotherapy (fSRT) for recurrent GBM.  
Materials and Methods: From September 2007 to December 2010, 17 
patients diagnosed with recurrent GBM after prior treatment with 
total resection followed by post-operative radiation (60Gy) and 
temozolomide were treated via re-irradiation using fSRT (including 
robotic assisted linear accelerator based fSRT and Cyberknife based 
fSRT). In all cases, recurrence was noted within the high-dose 
radiation therapy portal. Treatment consisted of a cumulative dose of 
2500cGy via 500cGy fractions prescribed to the D95 of the PTV 
(defined as GTV + 3mm).  
Results: Of the 17 patients treated, a radiographic response was 
observed in 8 (47%), while persistent tumor progression was noted in 9 
(53%). Median survival was 11.2 months for all patients, while median 
survival was 15.1 months in patients experiencing a radiographic 
response. Toxicity included limited alopecia and minor fatigue.  
Conclusions: Although the clinical management of recurrent GBM is 
challenging, the present data demonstrates significant salvage rates 
with acceptable morbidity. Fractionated SRT provides a viable 
alternative to other potential treatment options including re-resection 
and systemic therapy.  
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Purpose/Objective: Linac-based stereotactic radiotherapy (SRT) has 
been employed in the Department of Radiation Oncology, of European 
Institute of Oncology, EIO, Milan, Italy since 3/2003 and more than 
400 patients (pts) have been treated so far for brain metastases. In 
12/2011 CyberKnife Unit was installed in EIO. The objective of this 
study is to evaluate feasibility and acute toxicity profile of CBK-SRT 
for brain metastases in the first 8 months of clinical activity of the EIO 
CyberKnife. 
Materials and Methods: Inclusion criteria: for this retrospective study 
were as follows: 1) adult patients; 2) with up to 3 brain metastases 
(mets); 3) that underwent CBK-SRT at EIO between 12/2011 and 
10/2012 and 4) gave written informed consent for the treatment. 
Previous radiotherapy or concomitant systemic therapy was allowed. 
Treatment protocol: Contouring was based on the computer 
tomography (CT) and contrast medium magnetic resonance (MR). 
Treatments planning was performed using a MultiPlan® 4.5 treatment 
planning system (Accuray, Inc.). Sequential Optimization inverse 
planning algorithm was used: treatment plan typically involved 100-
200 beams, using 1-3 fixed circular collimators, which ranged in size 
from 5-60 mm. 6D skull tracking was used for intracranial lesions. It 
was based on rigid body registration of bony landmarks of the 
patient’s head to track intracranial targets and automatically correct 
for the translational or rotational shift that occurs during the 
treatment. Clinical monitoring: CBK-SRT was performed on the out-
patient basis. Steroid premedication was administrated. The toxicity 
was evaluated with use of Radiation Therapy Oncology 
Group/European Organization for Research and Treatment of Cancer 
(RTOG/EORTC) criteria. 
Results: Between 12/2011 and 10/2012 consecutive 85 pts were 
treated: primary diagnosis included lung (38 pts), breast (29 pts) and 
other malignancies (18 pts). Median age was 60 years (range, 37-82 
years). In all pts single brain metastasis was treated, while in 16, 4 
and 1 pts – 2, 3 and 4 lesions were treated, respectively (in 1 pt 
lesions were treated metachronously). CBK-SRT consisted in first 
radiotherapy and re-irradiation in case of 78 (92%) and 7 lesions, 
respectively. Median CBK-SRT dose was 20 Gy (range, 8-25 Gy)/1 
fraction (range, 1-5 fractions). All patients completed planned CBK-
SRT and no acute toxic event was registered. 
Conclusions: CyberKnife-based SRT is a feasible approach for limited 
brain metastatic disease offering short and well accepted treatment 
with low toxicity profile. Further investigation is warranted in order to 
evaluate the tumor control and late toxicity. The optimal combination 
with systemic treatment or surgery should also be defined.  
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Purpose/Objective: Stereotactic ablative body radiotherapy (SBRT, 
SABR) is being increasingly applied because of its high local efficacy, 
for small lung tumors and oligometastatic patients (pts). However, the 
optimum dosage is still under discussion. Here, we report data on 30 
lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 26 
patients, as part of a dose escalation study program, treated between 
2007 and 2011 by TomoTherapy SBRT. 
Materials and Methods: SBRT was performed with total doses of 54 Gy 
in 6 fractions. Eight pts were affected by stage I NSCLC, 18 were pts 
with oligo-recurrence cancer in the lung. Median age was 69.7 yrs (45-
91). In each patient a planning 18FDG-PET/CT was acquired in 4D-
mode to define a personalized ITV as a GTVs sum and the PTV with 
appropriate ITV expansions. Before each fraction a Mega-Voltage CT 
(MV-CT) was acquired for patient repositioning. Three-monthly follow-
up CT scans were supplemented by FDG-PET/CT if clinically indicated. 
Results: The median follow-up period was 22 months (range, 2-46 
months). Local progression-free survival rates was 70%, Overall 
survival rates was 96%. 21 and 20 pts had G0 acute and late toxicity, 
while 5 and 6 patients experienced respectively acute and late G1 
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pulmonary complications in according to the Radiation Therapy 
Oncology Group toxicity criteria. 
Conclusions: Our preliminary data suggested that radical treatment 
with SBRT is safe, feasible and provides a chance for long-term 
survival by offering favourable local control. 4D CT/PET planning and 
daily MV-CD evaluation are effective in target repositional accuracy 
for lung SBRT.  
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Purpose/Objective: Radiosurgery is an emerging radiation technique 
for the treatment of liver metastases, with encouraging local control 
rates and the ability to spare normal liver tissue radiation toxicity. 
The aim of this study was to demonstrate the feasibility of linac-based 
radiosurgery for liver metastases in terms of plan quality, dosimetric 
accuracy and treatment efficiency. In addition, the early clinical 
results are reported. 
Materials and Methods: Nine patients with liver lesions, enrolled in a 
prospective dose escalation study, were treated using Volumetric 
Modulated Arc Therapy. Patients immobilization was performed by 
means of the stereotactic body frame (SBF, Elekta, Crawley, UK). 
Clinical volumes were defined on CT-scans, PET/CT and MRI. The CTV 
was defined as the GTV. The PTV was individually defined for each 
patient based on Internal Margin (IM) and Set-up Margin (SM) 
assessment. The SM was set at 3 mm. OARs were the normal liver 
(liver minus CTV), spinal cord, esophagus, stomach, duodenum, small 
bowel and kidneys. Plans were generated with Elekta ERGO++ TPS, 
with a single arc rotation, using pencil beam algorithm with 
inhomogeneity correction for dose calculation. All patients were 
accrued at 26 Gy single fraction dose prescription. The prescription 
isodose surface (IDS) was selected as the greatest IDS fulfilling the two 
following criteria: 95% of PTV reached 100% of the prescription dose 
and 99% of PTV reached a minimum of 90% of prescription dose. 
Constraints for OARs were: healthy liver (700 cc < 15 Gy; V7Gy<50% and 
V12Gy<30%); stomach and duodenum (Dmax<12.4 Gy); spinal cord 
(Dmax<14 Gy); kidneys (V10.6Gy<2/3) and heart (Dmax<22Gy). Plans 
quality was evaluated by conformity index (CI), conformation number 
(CN) and gradient index (GI). VMAT delivery parameters were 
recorded in terms of MUs and beam-in time. All plans underwent 
dosimetric verification by means of ion-chambers array, using 
absolute doses and gamma analysis. 
Results: Median PTV was 54.7 cc (range:14.6-102.9 cc). The dose-
volume constraints for OARs were observed in all patients. Median CI, 
CN and GI were 1.23 (range: 1.16-1.50), 0.81 (range: 0.66-0.87 ) and 
3.6 (range: 2.6-4.3), respectively. The median beam-on time and MU 
number were 8.1 min (range:7.6-8.5 min) and 3010 MUs (range: 2789-
3148 MUs), respectively. More than 95% of points passed the γ-test for 
every arc (coronal and sagittal planes) with criteria of 3%-3mm. 
Overall treatment was well tolerated with no radiation induced liver 
disease and dose limiting toxicity. 1 patients had acute toxicity grade 
1. At median follow-up of 9 months, 6 patients had complete 
remission, 3 partial remission and 0 local progression. 
Conclusions: Linac-based radiosurgery is a feasible, safe and effective 
modality to treat liver metastases supplying high plan quality and 
extreme clinical efficiency. Single fraction radiosurgery provides 
excellent local control with minimal side effects in patients with 
limited hepatic metastases.  
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Purpose/Objective: Target determination is a basic requirement in 
radiotherapy. Especially for thoracic targets, respiratory and cardiac 
motion has great influence on the irradiation plan. The idea of this 
work was to use motion information derived from gated PET/CT 
images to create a more appropriate irradiation plan. To validate this 
method a thorax phantom was developed, which is compatible with 
MRT, CT and PET.  
Materials and Methods: The thorax phantom includes organ 
compartments (lungs,heart, diaphragm), which are able to represent 
realistic respiratory and cardiac motion. A small source, filled with 
radioactivity, was attached to the diaphragm to simulate a lesion, 
which is moved identifiable in CT/MRT/PET. By using image-derived 
motion information from 4D PET and CT (at mid- and end-respiratory 
phases) acquisitions different irradiation plans were calculated with 
Eclipse TPS. During radiation, an ionization chamber was placed at the 
same position as the small source. The measured dose of the 
ionization chamber was compared to the calculated dose of the 
irradiation plan. 
Results: First tests showed the applicability of the proposed designs. 
The presence of the ionization chamber did not interfere with 
respiratory and cardiac motion. Using this setup, it is possible to 
examine various methods based on PET, CT and MRT information 
considering various types of lesion movement during radiation. First 
measurements showed a deviation of up to 3% between the measured 
and calculated dose by using 4D PET/CT information. 
Conclusions: Using the proposed thorax phantom setup, a quantitative 
simulation of image-based radiotherapy treatment has been 
successfully performed. The method is especially appropriative for 
Extracranial Stereotactic Radiotherapy by using 4D PET/CT 
information. 
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Purpose/Objective: The purpose was to evaluate the setup accuracy 
of the GTC headframe in 3D aspects from matching results between 
the planning CT and the pre-treatment MVCT of tomotherapy. 
Materials and Methods: 15 patients treated with the GTC headframe 
by tomotherapy-based stereotactic radiotherapy (Tomo-SRT) system. 
8 were treated by single-fraction radiosurgery while 7 were treated 
with fractionated radiotherapy. There were 50 sets of set-up data in 
the study. 
The planning CT was done with an N-shaped CT localizer & 0.625mm 
slice thickness. The pre-treatment MVCT was scanned with the N-
shaped CT localizer and fused with the planning CT images. 
Anatomical match was done with 'Bone technique registration', 'Super 
Fine Resolution' and 'Translation & Roll correction'. The online 
anatomical match result represented overall set-up error. The offline 
rod matching result by matching the rods of the N-shaped CT localizer 
in both planning CT and pre-treatment MVCT was taken as the 'perfect 
match', which would represent the intrinsic systematic error. The true 
set-up error would be as follows: 
 
  
Similar matching methods were repeated, except the correction 
method was changed to be 'Translation + Pitch + Roll + Yaw', to 
simulate 'Ideal SRT' if a 6-degree couch was available. 
The matching results were recorded. The mean and standard 
deviation were calculated. 
Results: In Table 1, the mean values of all directions and rotations in 
both online & offline matching were within the tolerance of 
stereotactic radiotherapy (SRT), i.e. ±1mm & ±1°, except in the 
vertical direction. However, the true set-up error was all within the 
tolerance. 
